Multiple myeloma is a hematological malignancy.Over the past few decades,high-dose melphalan followed by autologous hematopoietic stem cell transplantation has emerged as the core component of the first treatment plan for patients with multiple myeloma.Induction therapy,autologous hematopoietic stem cell transplantation,and subsequent consolidation and maintenance therapy are the basic frameworks of multiple myeloma treatment.The introduction of anti-CD38 monoclonal antibodies,such as daratumumab,has altered the treatment paradigm for transplant-eligible patients with multiple myeloma,with quadruple therapy becoming the new standard of care for induction therapy.The treatment landscape for myeloma is undergoing a transformative shift with the advent of powerful new immunotherapies.This article reviews the research advances of autologous hematopoietic stem cell transplantation in multiple myeloma in the era of new drugs and new therapeutics.
维普
万方数据